Beta Bionics Stock

betabionics.comHealthcare / Medical DevicesFounded: 2015Funding to Date: $132MM

Beta Bionics, founded in 2015, is a medical technology company, and the creator of a bionic pancreas that aims to make diabetes care more manageable. Their iLet Bionic Pancreas is an automated insulin delivery system that can calculate doses, aiming to reduce the need for users to make decisions about their diabetes management.

Register for Details

For more details on financing and valuation for Beta Bionics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Beta Bionics.

Register Today

Beta Bionics investors also invested in these private companies

Farallon Capital Management
Eventide Asset Management
Pura Vida Investments
Five Stones Investment Group


Management Team

Toby Milgrome
Edward Damiano
Founder, President & Chief Executive Officer
Firas El-Khatib Ph.D
Co-Founder & Vice President, Autonomous Systems
Serafina Raskin
Vice President, Corporate Secretary & General Counsel
Stephen Feider
Chief Financial Officer
Steve Russell Ph.D
Chief Medical Officer

Board Members

Christian Foged
Novo Nordisk
Finny Kuruvilla Ph.D
Eventide Asset Management

Other companies like Beta Bionics in the Medical Devices sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Beta Bionics brings in $100M to expand artificial pancreas tech after FDA nod
In the wake of earning FDA clearance for its insulin pump and automated dosing software—which connect to a Dexcom continuous glucose monitor to create what’s known as a hybrid closed-loop system for diabetes management—Beta Bionics is raking in the dough. The Massachusetts-based company has pooled $100 million in series D equity funding, it announced this week.
FDA clears Beta Bionics' insulin pump and automated dosing software to create artificial pancreas
Artificial pancreas systems synchronize an insulin pump and continuous glucose monitor with the goal of delivering an almost completely hands-off approach to diabetes management—and the newest one cleared by the FDA aims to make that goal even easier to achieve.
Beta Bionics Receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System
The iLet is a pocket-sized, wearable investigational medical device that autonomously controls blood sugar in people with diabetes and other conditions --...
Updated on: Sep 20, 2023